Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 22;385(4):320-329.
doi: 10.1056/NEJMoa2107058. Epub 2021 Jun 30.

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

Mark G Thompson  1 , Jefferey L Burgess  1 , Allison L Naleway  1 , Harmony Tyner  1 , Sarang K Yoon  1 , Jennifer Meece  1 , Lauren E W Olsho  1 , Alberto J Caban-Martinez  1 , Ashley L Fowlkes  1 , Karen Lutrick  1 , Holly C Groom  1 , Kayan Dunnigan  1 , Marilyn J Odean  1 , Kurt Hegmann  1 , Elisha Stefanski  1 , Laura J Edwards  1 , Natasha Schaefer-Solle  1 , Lauren Grant  1 , Katherine Ellingson  1 , Jennifer L Kuntz  1 , Tnelda Zunie  1 , Matthew S Thiese  1 , Lynn Ivacic  1 , Meredith G Wesley  1 , Julie Mayo Lamberte  1 , Xiaoxiao Sun  1 , Michael E Smith  1 , Andrew L Phillips  1 , Kimberly D Groover  1 , Young M Yoo  1 , Joseph Gerald  1 , Rachel T Brown  1 , Meghan K Herring  1 , Gregory Joseph  1 , Shawn Beitel  1 , Tyler C Morrill  1 , Josephine Mak  1 , Patrick Rivers  1 , Brandon P Poe  1 , Brian Lynch  1 , Yingtao Zhou  1 , Jing Zhang  1 , Anna Kelleher  1 , Yan Li  1 , Monica Dickerson  1 , Erika Hanson  1 , Kyley Guenther  1 , Suxiang Tong  1 , Allen Bateman  1 , Erik Reisdorf  1 , John Barnes  1 , Eduardo Azziz-Baumgartner  1 , Danielle R Hunt  1 , Melissa L Arvay  1 , Preeta Kutty  1 , Alicia M Fry  1 , Manjusha Gaglani  1
Affiliations

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

Mark G Thompson et al. N Engl J Med. .

Erratum in

Abstract

Background: Information is limited regarding the effectiveness of the two-dose messenger RNA (mRNA) vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) in preventing infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and in attenuating coronavirus disease 2019 (Covid-19) when administered in real-world conditions.

Methods: We conducted a prospective cohort study involving 3975 health care personnel, first responders, and other essential and frontline workers. From December 14, 2020, to April 10, 2021, the participants completed weekly SARS-CoV-2 testing by providing mid-turbinate nasal swabs for qualitative and quantitative reverse-transcriptase-polymerase-chain-reaction (RT-PCR) analysis. The formula for calculating vaccine effectiveness was 100% × (1 - hazard ratio for SARS-CoV-2 infection in vaccinated vs. unvaccinated participants), with adjustments for the propensity to be vaccinated, study site, occupation, and local viral circulation.

Results: SARS-CoV-2 was detected in 204 participants (5%), of whom 5 were fully vaccinated (≥14 days after dose 2), 11 partially vaccinated (≥14 days after dose 1 and <14 days after dose 2), and 156 unvaccinated; the 32 participants with indeterminate vaccination status (<14 days after dose 1) were excluded. Adjusted vaccine effectiveness was 91% (95% confidence interval [CI], 76 to 97) with full vaccination and 81% (95% CI, 64 to 90) with partial vaccination. Among participants with SARS-CoV-2 infection, the mean viral RNA load was 40% lower (95% CI, 16 to 57) in partially or fully vaccinated participants than in unvaccinated participants. In addition, the risk of febrile symptoms was 58% lower (relative risk, 0.42; 95% CI, 0.18 to 0.98) and the duration of illness was shorter, with 2.3 fewer days spent sick in bed (95% CI, 0.8 to 3.7).

Conclusions: Authorized mRNA vaccines were highly effective among working-age adults in preventing SARS-CoV-2 infection when administered in real-world conditions, and the vaccines attenuated the viral RNA load, risk of febrile symptoms, and duration of illness among those who had breakthrough infection despite vaccination. (Funded by the National Center for Immunization and Respiratory Diseases and the Centers for Disease Control and Prevention.).

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403-416. - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603-2615. - PMC - PubMed
    1. Thompson MG, Burgess JL, Naleway AL, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers — eight U.S. locations, December 2020–March 2021. MMWR Morb Mortal Wkly Rep 2021;70:495-500. - PMC - PubMed
    1. Paden CR, Tao Y, Queen K, et al. Rapid, sensitive, full-genome sequencing of severe acute respiratory syndrome Coronavirus 2. Emerg Infect Dis 2020;26:2401-2405. - PMC - PubMed
    1. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-560. - PubMed

Publication types

MeSH terms